ArticleNaunyn-Schmiedeberg's archives of pharmacology2006
Enhancement of vascular smooth muscle cell migration by urotensin II.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 23 citations in OpenAlex.
- Targeting the Urotensin II/UT G Protein-Coupled Receptor to Counteract Angiogenesis and Mesenchymal Hypoxia/Necrosis in Glioblastoma.Frontiers in cell and developmental biology · 2021Article
- The G Protein-Coupled Receptor UT of the Neuropeptide Urotensin II Displays Structural and Functional Chemokine Features.Frontiers in endocrinology · 2017Review
- Signaling switch of the urotensin II vasosactive peptide GPCR: prototypic chemotaxic mechanism in glioma.Oncogene · 2015Article
- The orally active urotensin receptor antagonist, KR36676, attenuates cellular and cardiac hypertrophy.British journal of pharmacology · 2015Article
- Intra-ventral tegmental area microinjections of urotensin II modulate the effects of cocaine.Behavioural brain research · 2015Article
- Autocrine Human Urotensin II Enhances Macrophage-Derived Foam Cell Formation in Transgenic Rabbits.BioMed research international · 2015Article
- Urantide improves atherosclerosis by controlling C-reactive protein, monocyte chemotactic protein-1 and transforming growth factor-β expression in rats.Experimental and therapeutic medicine · 2014Article
- The urotensin II receptor antagonist, urantide, protects against atherosclerosis in rats.Experimental and therapeutic medicine · 2013Article
- Effects of urotensin II and its specific receptor antagonist urantide on rat vascular smooth muscle cells.Bosnian journal of basic medical sciences · 2013Article
- Moxibustion Inhibits the ERK Signaling Pathway and Intestinal Fibrosis in Rats with Crohn's Disease.Evidence-based complementary and alternative medicine : eCAM · 2013Article
- DUX4 differentially regulates transcriptomes of human rhabdomyosarcoma and mouse C2C12 cells.PloS one · 2013Article
- Urotensin upregulates transforming growth factor-β1 expression of asthma airway through ERK-dependent pathway.Molecular and cellular biochemistry · 2012Article
- Urotensin II-induced signaling involved in proliferation of vascular smooth muscle cells.Vascular health and risk management · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The effects of urotensin II (UII) on migration of human aortic smooth muscle cells (HASMCs) were investigated. UII (1-100 nM) significantly increased velocity of HASMC motility in a concentration-dependent manner. Stress-fiber formation and ERK (p44/p42) activity were also increased by UII. U0126 and PD 98059, MEK inhibitors, abolished the effects of UII on motility velocity and stress-fiber formation. These results suggest that UII enhances HASMC migration through activation of an ERK-dependent pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.